Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02975934 · OUTCOME

Trough Plasma PK (Cmin) of Rucaparib Based on Sparse Sampling

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency · Source last updated 2025-07-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
ng/mL
Interval / dispersion
Full Range
Time frame
From enrollment to week 5 of dosing

What was measured

Mean trough PK plasma concentration over time in the safety population with at least one PK sample collected at timepoints week 5, 9, 13 and 17; only Week 5 data presented.

Analysis population: Safety Population with at least 1 PK sample collected.

Groups in this outcome

Rucaparib

Oral rucaparib (monotherapy). Rucaparib: Rucaparib will be administered daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rucaparib228

Reported measurements

Source class 1
Values in ng/mL · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Rucaparib1310Not reported5.54180Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5.5
        upper Limit
        4180
        value
        1310
denoms
  1. counts
    1. group Id
      OG000
      value
      228
    units
    Participants
description
Mean trough PK plasma concentration over time in the safety population with at least one PK sample collected at timepoints week 5, 9, 13 and 17; only Week 5 data presented.
dispersion Type
Full Range
groups
  1. description
    Oral rucaparib (monotherapy). Rucaparib: Rucaparib will be administered daily.
    id
    OG000
    title
    Rucaparib
param Type
MEDIAN
population Description
Safety Population with at least 1 PK sample collected.
reporting Status
POSTED
time Frame
From enrollment to week 5 of dosing
title
Trough Plasma PK (Cmin) of Rucaparib Based on Sparse Sampling
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice